Search
Deferoxamine
go.drugbank.com/drugs/DB00746ApprovedInvestigationalNatural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
Products: Desferal 500mg Powder for Solution for Injection, Deferoxamine Mesylate for InjectionTigecycline
go.drugbank.com/drugs/DB00560ApprovedInvestigationalTigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was gra...
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseProducts: Tigaciv 50mg Lyophilized Powder for Concentrate for Solution for Infusion, TIGECYCLINE SANDOZ POWDER FOR SOLUTION FOR INFUSION 50 MG PER VIALLurbinectedin
go.drugbank.com/drugs/DB12674ApprovedInvestigational[A214331] On June 15, 2020, the FDA granted accelerated approval and orphan drug designation to lurbinectedin for the treatment of adult patients with metastatic SCLC who have experienced disease progression
Products: ZEPZELCA POWDER FOR SOLUTION FOR INFUSION 4MG/VIALFludarabine
go.drugbank.com/drugs/DB01073ApprovedInvestigationalFludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
Products: FLUDARABINE PHOSPHATE POWDER FOR SOLUTION FOR INJECTION/ INFUSION USP, Fludarabine Kabi 50mg Lyophilized Powder for Solution for Injection or InfusionBlinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigational[L44311] Full approval for this indication was granted in June 2023. … It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients.
Products: BLINCYTO POWDER FOR INFUSION 35 MCG/VIAL, BLINCYTO (Blinatumomab) for injection 35 mcg/vialAvalglucosidase alfa
go.drugbank.com/drugs/DB16099ApprovedInvestigationalAvalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase … GAA is an essential enzyme that hydrolyzes glycogen into free glucose for use in cellular functions.
Products: NEXVIAZYME 100mg Powder for Concentrate for Solution for InfusionBemiparin
go.drugbank.com/drugs/DB09258ApprovedWithdrawnInterestingly, current research is underway for the potential benefit of bemiparin in the treatment of tumors and diabetic foot ulcers [L1468, A7866]. … These heparins have lower anti-thrombin activity than the traditional low molecular weight heparins and act mainly on factor-Xa, reducing the risk of bleeding due to selectivity for this specific clotting
Products: HIBOR 2,500 IU ANTI XA/0.2ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGES, HIBOR 10,000 IU ANTI XA/0.4 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGESSulfur hexafluoride
go.drugbank.com/drugs/DB11104ApprovedInvestigationalin adult patients with suboptimal echocardiograms •in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients … Sulfur hexafluoride is an ultrasound contrast agent indicated for use •in echocardiography to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border
Products: SONOVUE POWDER FOR DISPERSION FOR INJECTION 8 microlitres/mlFerric derisomaltose
go.drugbank.com/drugs/DB15617ApprovedInvestigationalIron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocyt...
Products: MONOFER® SOLUTION FOR INJECTION OR INFUSION 100 MG/ML, Monofer 100 mg/ml solution for injection/infusion in vialsArtesunate
go.drugbank.com/drugs/DB09274ApprovedInvestigationalArtesunate is indicated for the initial treatment of severe malaria.[L14099] The World Health Organization recommends artesunate as first line treatment for severe malaria. … [L890] Artesunate was developed out of a need for a more hydrophilic derivative of [artemisinin].[A203948] Artesunate was granted FDA approval on 26 May 2020.[L14099]
Products: ARTESUNATE FOR INJECTION, ARTESUN POWDER FOR INJECTION 60 MG